Ziteng et al. constructed a pan-cancer predictive index of anti-HER2 therapies across 33 tumor types, including breast cancer, which highlighted the importance of incorporating transcriptional patterns into the assessment of HER2 status for better patient selection 9. Here, ERBB2 is linked to neoplasm.